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difference. The observed loss of FEV1 was neither 
a time-dependent nor a dose-dependent effect in 
the withdrawal group, as compared with the main-
tenance group. A difference of 38 ml between 
groups became apparent only after the final step 
of inhaled glucocorticoid withdrawal and did not 
change to a meaningful extent thereafter.
Singanayagam et al. point out that we included 
only patients receiving maintenance therapy 
with inhaled glucocorticoids who had a history 
of exacerbation in the previous year. This reflects 
current treatment recommendations. In the re-
cent Indacaterol: Switching Nonexacerbating Pa-
tients with Moderate COPD from Salmeterol/
Fluticasone to Indacaterol (INSTEAD) trial in-
volving patients with moderate COPD who had 
no exacerbations during the previous year, switch-
ing patients from a combination of a long-acting 
β-agonist (LABA) and an inhaled glucocorticoid 
to an ultra-long-acting LABA did not increase 
the exacerbation rate during 26 weeks of treat-
ment.1 We agree that clinicians prescribe inhaled 
glucocorticoids because they see value in their 
use, but there may be reasons other than the 
prevention of exacerbations for this practice, such 
as the convenience of combination inhalers.2
Brightling et al. suggest that we stratify our 
results according to the baseline blood eosino-
phil count. A major objective of the WISDOM 
trial was to identify a subgroup of patients who 
have a response to inhaled glucocorticoids,3 but 
so far we have not been able to identify a respon-
sive phenotype on the basis of data from our 
prespecified subgroups.
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Fractional Flow Reserve–Guided PCI
To the Editor: De Bruyne et al. (Sept. 25 issue)1 
conclude that the high rate of death within 7 days 
after randomization in the percutaneous coro-
nary intervention (PCI) group in their study was 
due to benign periprocedural infarctions, but there 
were more myocardial infarctions in the medical-
therapy group after the initial 7 days following 
randomization. However, after 7 days, there were 
more revascularizations in the medical-therapy 
group; this suggests that there were more peri-
procedural infarctions.2 Thus, the high rate of 
myocardial infarctions after the initial 7 days fol-
lowing randomization in the medical-therapy 
group could also be caused by the same benign 
periprocedural infarctions, since there was no dif-
ference in overall mortality.2 Unfortunately, the 
percentage of late myocardial infarctions caused 
by periprocedural infarctions was not reported.
Furthermore, the primary outcome in this 
study was driven mainly by urgent revasculariza-
tion, which could have been confounded by the 
open-label nature of the study. Since patients in 
the medical-therapy group knew that they had 
untreated stenosis, they were more likely to re-
port symptoms.3 Coupled with bias from treat-
ing physicians, this would lead to a higher inci-
dence of hospitalization, cardiac catheterization, 
and ultimately revascularization.4 Therefore, a 
double-blind, controlled trial is required to de-
termine the true effect of fractional flow re-
serve–guided PCI on urgent revascularization.5
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The Authors Reply: Shah’s point with regard to 
periprocedural infarctions could be plausible. 
However, an analysis of the entire duration of the 
follow-up period shows that there were 8 peri-
procedural infarctions (1.8%) in the PCI group 
versus 5 (1.1%) in the medical-therapy group 
(hazard ratio, 1.59; 95% confidence interval [CI], 
0.52 to 4.86). Conversely, there were 18 spontane-
ous myocardial infarctions (4.0%) in the PCI 
group versus 25 (5.7%) in the medical-therapy 
group (hazard ratio, 0.70; 95% CI, 0.38 to 1.29); 
this provides support for our initial conclusions. 
As we acknowledged in our article, the aware-
ness of the presence of stenoses may indeed in-
fluence patients’ or physicians’ decisions. Yet, 
registry patients had a low number of events 
despite their awareness of functionally signifi-
cant coronary disease. Ensuring that patients and 
clinicians were unaware of the assigned treat-
ment theoretically could have added methodo-
logic rigor, but this hardly seems feasible. In ad-
dition, the largest meta-epidemiologic study to 
date showed no evidence of relevant bias associ-
ated with awareness of study-drug assignments 
by patients and therapists when objective out-
comes were used.1 Rather, outcome assessors 
should be unaware of study-drug assignments 
when they adjudicate these types of outcomes, 
as was the case in our trial.
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Health and Health Care in South Africa
To the Editor: Mayosi et al. (Oct. 2 issue)1 note 
that South Africa’s local challenges to improving 
health are a microcosm of worldwide impedi-
ments to better population health. The causal 
factors of inequality are complex interactions of 
sociopolitical–economic factors and cultural at-
titudes.
Similarly, it would be simplistic to attribute the 
origins and perpetuation of legislative discrimi-
nation to a moral failing and myopia unique to 
South Africans. To do so would be to accept the 
attribution error of apartheid — namely, that 
groups of people are inherently different. Politi-
cal oppression and social suffering arising from 
the failure to recognize common humanity and 
shared interest are not specific to one people or 
period.
The current global inequalities in health2 re-
flect the darkest history of South African soci-
ety. International legislative barriers to common 
access to, and benefit from, education, natural 
resources, and economic progress are associated 
with profound differences in health outcomes. 
As global citizens today, we should recognize 
and act on the fundamental lesson of apartheid’s 
local history: We are not that different.
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